Alk
Alk, officially known as Alk Abello A/S, is a leading player in the biopharmaceutical industry, headquartered in Denmark (DK). Founded in 1923, the company has established itself as a pioneer in allergy immunotherapy, focusing on innovative treatments for allergic conditions. With a strong presence in Europe and North America, Alk is dedicated to improving the quality of life for allergy sufferers through its advanced products. The company’s core offerings include sublingual and injectable immunotherapy solutions, which are distinguished by their efficacy and patient-friendly administration methods. Alk's commitment to research and development has positioned it as a market leader, achieving significant milestones such as the introduction of the first sublingual tablet for grass pollen allergy. With a robust portfolio and a focus on patient-centric solutions, Alk continues to drive advancements in allergy treatment.
DitchCarbon Score
How does Alk's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alk's score of 47 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alk's reported carbon emissions
In 2023, ALK-Abelló A/S reported total greenhouse gas emissions of approximately 69,555,000 kg CO2e, with emissions distributed across various scopes: 5,128,000 kg CO2e (Scope 1), 5,917,000 kg CO2e (Scope 2), and 64,067,000 kg CO2e (Scope 3). The company has made significant strides in reducing its carbon footprint, achieving a 41% reduction in absolute Scope 1 and 2 emissions from a 2019 baseline by 2022. Looking ahead, ALK-Abelló has committed to further reductions, targeting a 42% decrease in absolute Scope 1 and 2 emissions by 2030, using 2022 as the base year. Additionally, the company aims for 80% of its suppliers to establish science-based targets by 2028, covering emissions from purchased goods and services, capital goods, and transportation activities. The emissions data and reduction targets are sourced directly from ALK-Abelló A/S, with no cascaded data from parent organizations. The company's climate commitments align with industry standards, reflecting a proactive approach to sustainability in the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 5,479,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 3,003,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | 4,244,000 | 000,000 | 000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alk is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
